Hugel has been developing and introducing new technologies based on botulinum toxin manufacturing technology in cooperation with the best researchers at home and abroad, mainly in the field of cosmetic surgery and therapeutics.
Hugel creates new value through continuous management innovation and is evolving into a truly global biopharmaceutical company.VIEW MORE
Hugel has been developing into a truly global biopharmaceutical company by constantly creating new value, and we will continue to lead the way for Korea to become a powerhouse in the bio sector.
Hugel Achieved Record-High Revenue and O..
Hugel Resolves to Retire 371,563 shares..
Hugel Wins $70 Million Export Tower Awa..
Hugel Breaks 3Q Quarterly and Cumulativ..
Hugel resubmits BLA for its botulinum t..
Hugel Appoints Co-CEOs...Strengthens Bu..
We will provide maximum investment value through securing future growth engines.